The Gene Therapy the FDA Rejected Twice Just Got Approved

The results from Rocket's Phase 1/2 trial were striking. Every single patient survived at 12 months post-infusion. That's a 100% survival rate in a disease that kills three out of four untreated kids before kindergarten. Patients saw meaningful reductions in serious infections, improved wound healing, and better skin lesions. No serious adverse events were linked to the treatment.

The FDA granted accelerated approval based on increased CD18 protein levels on immune cells, a surrogate marker that suggests the therapy is doing exactly what it should. The label restricts use to pediatric patients with severe LAD-1 who lack a matched sibling donor for transplant, essentially the kids with the fewest options and the highest stakes.

Two Rejections, Zero Safety Concerns

So if the drug worked beautifully, why did the FDA reject it? Twice?

The Complete Response Letters were about Chemistry, Manufacturing, and Controls (CMC) issues. In plain English: the FDA wanted more data about how the therapy is made, not whether it works. Think of it like a restaurant that makes incredible food but keeps failing its health inspection. The dishes are perfect; the kitchen documentation needs work.

CMC rejections are more common than you'd think in gene therapy. These products are living medicines made from a patient's own cells. Quality control is enormously complex. Every batch is essentially custom, and the FDA (rightfully) holds manufacturers to exacting standards on consistency and process documentation.

Rocket aligned on what needed fixing and resubmitted the application in October 2025. The FDA accepted the resubmission and set a target decision date of March 28, 2026.

A Win for the Comeback Kids

Kresladi's approval is a milestone for several reasons. It validates that CMC problems, while frustrating and time-consuming, are solvable. Companies with strong clinical data shouldn't panic when they get a manufacturing-related CRL. The drug also earned Rocket eligibility for a Rare Pediatric Disease Priority Review Voucher, which can be sold to larger drugmakers for hundreds of millions of dollars.

But let's be honest about the commercial picture. With roughly 25 new U.S. cases per year, Kresladi will never be a blockbuster in the traditional sense. Rocket is expected to charge millions of dollars per treatment, consistent with other one-time gene therapies for ultra-rare diseases. Pre-approval analyst projections pegged Rocket's total revenue (including pipeline assets beyond Kresladi) at around $165 million by 2029, growing to $300 million by 2030.

The real significance is broader. Kresladi joins a small but growing club of gene therapies tackling rare genetic diseases that previously had no good answers. And in a landscape where some approved gene therapies have already been pulled from the market due to low demand (Pfizer's hemophilia B therapy Beqvez was discontinued in 2025), Kresladi's path to patients will be closely watched as a test case for ultra-rare gene therapy commercialization.

What This Means for Families

For the handful of families who receive a LAD-1 diagnosis each year, the calculus just changed dramatically. Instead of hoping for a matched donor and bracing for a risky transplant, there's now a one-time treatment that corrected the underlying genetic defect in every patient studied.

It took two rejections, a full resubmission, and two years longer than anyone wanted. But Kresladi is here. Sometimes the best comeback stories take a little longer to write.